Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Inclusion Criteria:

1. Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A/B intact) per WHO 2021 tumor classification.
2. Completed external beam radiation therapy per standard of care.
3. Patients with GBM: Must have received at least 80% of planned daily doses of TMZ during chemoradiation. Patients with astrocytoma: Must have tolerated adjuvant TMZ treatment through at least 2 and not more than 4 cycles.
4. Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.
5. Willing to abstain from intercourse or use acceptable contraceptive methods.
6. If taking corticosteroids, must be on a stable or decreasing dose.

Exclusion Criteria:

1. Recent history of recurrent or metastatic cancer that could confound response assessments
2. Prior systemic chemotherapy other than temozolomide during external beam radiation therapy (for patients with GBM) or adjuvant temozolomide through up to 4 pre-study cycles (for patients with astrocytoma).
3. Prior Optune treatment.
4. Active infection or serious intercurrent medical illness.
5. Poorly controlled seizures.
6. Significant cardiac disease within 6 months of enrollment.
7. Poorly controlled diabetes.
8. Use of another investigational agent within 30 days of enrollment.